Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Miami, Florida 33136


RATIONALE: Giving fluconazole may be effective in preventing or controlling mucositis caused by radiation therapy to the head and neck. PURPOSE: Randomized phase II/III trial to study the effectiveness of fluconazole in preventing mucositis in patients undergoing radiation therapy for head and neck cancer.

Study summary:

OBJECTIVES: - Determine the effect of prophylactic antifungal therapy with fluconazole on the incidence and severity of radiation-associated mucositis/thrush in patients with head and neck cancer undergoing definitive radiotherapy. OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients undergo standard hyperfractionated radiotherapy 5 days a week for 5-5.6 weeks. Patients receive oral fluconazole on days 1-4 and 28-31 of radiotherapy. - Arm II: Patients undergo radiotherapy as in arm I. Patients who develop a microbiologically proven fungal infection or clinically evident oral cavity and/or oropharyngeal thrush may receive fluconazole as in arm I. PROJECTED ACCRUAL: At least 42 patients (26 per arm) will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically proven head and neck cancer undergoing definitive radiotherapy PATIENT CHARACTERISTICS: Age: - Over 21 Performance status: - Karnofsky 70-100% Hematopoietic: - Not specified Hepatic: - SGOT and SGPT less than 2 times normal - Alkaline phosphatase less than 2 times normal Renal: - Not specified Other: - No history of hypersensitivity to fluconazole - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified Other - At least 2 months since prior antifungal agents - Not currently receiving phenytoin, hydrochlorothiazide, or warfarin - If these medications are initiated during study therapy, medication serum levels and electrolytes are monitored for possibility of drug interaction



Primary Contact:

Study Chair
Arnold M. Markoe, MD, ScD
University of Miami Sylvester Comprehensive Cancer Center

Backup Contact:


Location Contact:

Miami, Florida 33136
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.